May 1, 2020
MediSieve Joins LondonLAB Project Run by the London Business School
MediSieve has joined a 10-week data analysis program run by the London Business School,
LONDON – May 01, 2020 – MediSieve has joined a 10-week data analysis program run by the London Business School. MediSieve already has strong ties with the LBS since several team members are graduates of its programmes and individual trainings.
Participating in the 10-week programme was a great opportunity for MediSieve to expand their network as well as gain novel insights into the company's research data. The extensive analysis run by the LBS students provided MediSieve with high-quality tools for data management and evaluation. MediSieve's CEO and Founder George Frodsham said:
"It is great to see how passionate students are about what they do. It was great to collaborate with such a community. The results from the programme highlighted what issues need to be adressed in out business model and will definetely be implemented into MediSieve!"
The two student groups that performed a deep statistical analysis of MedSieve's data assisted in creating an efficient data assessment tool. Both the students and the company benefited from the project. The students gained practice and strengthened their communication skills, whilst the company gained deeper insight into their data. The project laid the groundwork for a future in which experiment planning is efficient and data-driven.
More information about the program can be found here:
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: